09-05-2024 | Cytostatic Therapy | ASO Author Reflections
ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
Authors:
Daisaku Yamada, MD, PhD, Shogo Kobayashi, MD, PhD, Hidenori Takahashi, MD, PhD, Yoshifumi Iwagami, MD, PhD, Hirofumi Akita, MD, PhD, Kei Asukai, MD, PhD, Junzo Shimizu, MD, PhD, Terumasa Yamada, MD, PhD, Masahiro Tanemura, MD, PhD, Shigekazu Yokoyama, MD, PhD, Masanori Tsujie, MD, PhD, Tadafumi Asaoka, MD, PhD, Yutaka Takeda, MD, PhD, Osakuni Morimoto, MD, PhD, Akira Tomokuni, MD, PhD, Yuichiro Doki, MD, PhD, Hidetoshi Eguchi, MD, PhD
Published in:
Annals of Surgical Oncology
Login to get access
Excerpt
The optimal neoadjuvant chemotherapy (NAC) regimen for patients with R/BR-PDAC remains uncertain.
1‐5 We conducted the first trial comparing the efficacy and safety of two candidate regimens: GEM+nPTX (GA) and GEM+S-1 (GS). …
